Why Luminate

Horizon Europe’s "Good Health & Well-being" (SDG 3)

Promoting overall health and well-being through innovative research and solutions.

Enhancing Patient-Centered Healthcare

Focusing on the needs and preferences of patients to improve their healthcare experience.

Improving Treatment Accessibility

Expanding access to effective treatments for a broader population, ensuring equitable healthcare for all.

Primary Impact of LUMINATE

From Ambition to Excellence: Where Will Our Impact Be Seen?

The impact of traumatic knee injuries is profound and far-reaching. Each year, two million traumatic injuries to the soft tissue in joints (cartilage) occur. Of these, 50% of severe cases lead to Post-Traumatic Osteoarthritis (PTOA) within a decade. Traumatic injuries account for 12% of all osteoarthritis cases, significantly affecting the quality of life. Notably, women represent 62% of total joint arthroplasties, highlighting a strong gender bias in osteoarthritis development.

Related Goals: To address these challenges, our efforts align with several key objectives:

Economic Impact

Financial Burden of PTOA Injury

The economic impact of Osteo Arthritis is substantial. In Europe, costs are estimated at €76 billion annually due to treatment, rehabilitation, and productivity loss.
Each knee replacement surgery costs €12,000 on average, plus post-operative expenses. Additionally, 50% of younger patients (under 50 years) require revision surgeries, which doubles healthcare costs.

Economic Impact

Innovative Solutions

To mitigate these impacts, LUMINATE introduces several groundbreaking approaches:

Single-Stage Bioprinting

This technique eliminates the need for multiple surgeries, reducing hospital stays and rehabilitation expenses.

Preventing Progression to Osteoarthritis (OA)

By stopping OC injuries from worsening, LUMINATE significantly cuts long-term treatment costs.

Less Need for Revision Surgeries

Patients avoid expensive implant replacements, particularly younger individuals who face multiple interventions in their lifetime.

Faster Return to Work

By enabling quicker recovery, patients experience less productivity loss, reducing the economic impact on employers and national healthcare systems.

Project timeline

Towards Innovative Solutions

Kick-OFF meeting
01/2025
MS 1 – Design requirements for EndoFlight bioprinting suite established
06/2025
MS 2 – Photoresins for bone and cartilage developed and validated
12/2025
General Assembly 2
01/2026
MS 3 – EndoFlight developed and validated
06/2026
MS 4 – Protocols to create the cartilage bioresin developed and validated
12/2026
MS 5 – Resin production, cell manufacturing and printing protocols at GMP, regulatory pathways, for the EndoFlight bioprinting suite defined
12/2027
MS 6 – Final version of the LUMINATE approach
12/2028